Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.
Correction of hypokalemia,Prevention of hypokalemia in patients receiving potassium-depleting therapies,Intravenous source of calories (dextrose component)
Cardiac resuscitation (e.g., asystole, pulseless electrical activity) due to hyperkalemia, hypocalcemia, or calcium channel blocker overdose,Severe hypocalcemia,Treatment of hypermagnesemia,Treatment of calcium channel blocker overdose,Cardiopulmonary bypass,Intraoperative floppy iris syndrome (off-label)
Intravenous infusion; typical adult dose: 10-20 m Eq per hour, not exceeding 40 m Eq per dose and 200 m Eq per day, titrated based on serum potassium and ECG monitoring.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism.
2-4 hours in patients with normal renal function; prolonged in renal impairment.
Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle.
Calcium chloride dissociates to release calcium ions which are primarily regulated by the kidney; no significant hepatic metabolism.
Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion.
Primarily renal (80-90% as ionized calcium); minor fecal elimination (<10%).
Potassium is not significantly protein-bound (<10%). Dextrose has negligible protein binding. No specific binding proteins identified for potassium; it exists as free ion in plasma.
Approximately 45-50% bound primarily to albumin.
Potassium Vd is approximately 0.5-0.6 L/kg, indicating distribution primarily into extracellular fluid. Total body potassium is ~50 m Eq/kg, with 98% intracellular. The clinical meaning: initial dose distributes into ECF before equilibrating with ICF; rapid IV administration can cause transient hyperkalemia.
0.5-0.6 L/kg; primarily distributed in extracellular fluid.
Intravenous administration yields 100% bioavailability. Oral potassium chloride has ~90-100% bioavailability, but this formulation is not for oral use. Dextrose only given IV; not applicable for oral.
Not applicable; administered only intravenously. Oral calcium salts have variable bioavailability (25-40%).
For GFR 30-50 m L/min: reduce infusion rate by 25%; GFR 15-29: reduce rate by 50%; GFR <15: avoid use or use with extreme caution at reduced rate, monitor potassium closely.
GFR 30-60 m L/min: Use with caution; monitor serum calcium and phosphate levels. GFR <30 m L/min: Avoid use or use only if benefit outweighs risk; reduce dose by 50% and monitor serum calcium and phosphate closely.
No specific Child-Pugh based adjustments; monitor serum potassium and acid-base status closely in hepatic impairment due to risk of hyperkalemia.
No dose adjustment recommended for Child-Pugh Class A or B. Child-Pugh Class C: Use with caution; monitor serum calcium and cardiac function due to potential for accumulation of calcium and effects on myocardial contractility.
Intravenous infusion; 0.5-1 m Eq/kg per dose, maximum 40 m Eq per dose, infused at rate not exceeding 0.5-1 m Eq/kg/hour; adjust based on serum potassium and clinical response.
IV: 0.2 m L/kg (20 mg/kg) of 10% solution, administered slowly at a rate not exceeding 0.5-1 m L/min. Dose may be repeated if needed. Maximum single dose: 1 g (10 m L).
Use lower initial infusion rates (e.g., 5-10 m Eq/hour) due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion.
No specific dose adjustment, but consider reduced renal function common in elderly; use lowest effective dose and monitor serum calcium, phosphate, and cardiac status. Infusion rate should be slow (0.5-1 m L/min) to avoid adverse effects.
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia. Accidental administration of undiluted concentrate can lead to cardiac arrest.
Do not administer by intracardiac injection due to risk of myocardial rupture and cardiac arrest.
Risk of hyperkalemia, especially in patients with renal impairment,Cardiac monitoring recommended during infusion,Avoid rapid intravenous administration,Use with caution in patients with cardiac disease, adrenal insufficiency, or acid-base disorders,May cause phlebitis at injection site
Extravasation can cause tissue necrosis; administer slowly to avoid hypercalcemia; use with caution in digitalis toxicity as hypercalcemia potentiates digoxin toxicity; monitor serum calcium levels; avoid in patients with renal failure unless severe hypocalcemia exists.
Hyperkalemia (serum potassium >5.5 m Eq/L),Severe renal failure with oliguria or azotemia,Concurrent use of potassium-sparing diuretics (unless under close monitoring),Acidosis (may worsen hyperkalemia),Crush injury or massive hemolysis (risk of acute hyperkalemia),Addison's disease (untreated)
Hypercalcemia, ventricular fibrillation during cardiac arrest, concurrent digitalis therapy (relative), patients with known hypersensitivity to calcium salts.
No specific food interactions with IV potassium chloride and dextrose. However, while on treatment, avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by your doctor, as concurrent dietary potassium may increase risk of hyperkalemia.
Avoid calcium-fortified foods and dairy products if serum calcium is elevated. High doses of vitamin D can increase calcium absorption, leading to hypercalcemia. Caffeine and alcohol may increase urinary calcium excretion, potentially reducing efficacy. Oxalate-rich foods (spinach, rhubarb) and phytate-rich foods (whole grains) bind calcium and may reduce absorption, but this is less relevant with IV administration.
No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No increased risk of congenital anomalies reported. However, maternal hyperkalemia or severe hypoglycemia may indirectly affect fetal well-being.
No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly needed; high doses may cause hypercalcemia in fetus (e.g., hypotonia, poor feeding). Intravenous administration near term may suppress fetal parathyroid function.
Potassium chloride and dextrose are normal constituents of breast milk. Supplementation does not significantly alter milk composition. No adverse effects in nursing infants expected. M/P ratio not applicable as substances are endogenous.
Calcium is excreted in breast milk but in normal physiological amounts. M/P ratio not established; supplemental calcium likely safe but high IV doses may increase milk calcium concentration. Monitor infant for hypercalcemia with prolonged high-dose maternal therapy.
No specific dose adjustments required due to pregnancy. Monitor for fluid overload in preeclampsia or compromised cardiac function. Glucose-containing solutions necessitate glucose monitoring in diabetes. Potassium supplementation should be guided by serum potassium levels.
No specific dose adjustment required; pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may necessitate higher doses to achieve desired serum calcium levels, but titrate to effect and serum calcium monitoring. Avoid bolus administration during labor; use slow IV infusion.
Potassium chloride 0.3% in dextrose 5% provides 40 m Eq/L of potassium and 50 g/L of dextrose. Administer via peripheral line; central line preferred for concentrations >40 m Eq/L. Never give IV push. Infusion rate should not exceed 10 m Eq/h or 200 m Eq/24h without cardiac monitoring. Contraindicated in severe hyperkalemia, renal failure with oliguria, and untreated Addison's disease. Use with caution in patients with cardiac disease, digoxin therapy, or metabolic acidosis. Monitor serum potassium and ECG continuously during infusion.
Calcium chloride provides approximately 3 times more elemental calcium per m L than calcium gluconate. Due to its high osmolality (approx. 2000 m Osm/L), it is a severe vesicant; central line administration is strongly preferred to prevent tissue necrosis if extravasation occurs. For peripheral IV, use a large bore vein with good blood flow and avoid hand/wrist veins. In cardiac arrest (e.g., hyperkalemia, calcium channel blocker overdose), give 10 m L of 10% solution (1 g) IV push; may repeat every 10 minutes if needed. Monitor serum calcium, magnesium, and phosphate levels; correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia. Contraindicated in digitalis toxicity (can precipitate fatal arrhythmias). Not for IM or SC use.
This medication is given through a vein to correct low potassium levels.,Report any pain, redness, or swelling at the IV site immediately.,You may experience increased thirst or urination due to the dextrose content.,Do not stop treatment abruptly without consulting your healthcare provider.,Inform your doctor of all medications you take, especially digoxin and diuretics.
Report any burning, pain, or swelling at the IV site immediately.,This medication increases calcium levels; do not take additional calcium supplements or antacids without doctor approval.,Calcium can interfere with the absorption of certain antibiotics (tetracyclines, fluoroquinolones) and thyroid medications; separate doses by at least 2-4 hours.,Avoid excessive intake of vitamin D or calcium-rich foods unless directed by your doctor.,Seek emergency care if you experience chest pain, irregular heartbeat, or muscle cramps.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.. CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Calcium ion is essential for normal cell function, including muscle contraction, nerve transmission, and blood coagulation. It acts as a positive inotrope by increasing myocardial contractility and also corrects hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose: 10-20 m Eq per hour, not exceeding 40 m Eq per dose and 200 m Eq per day, titrated based on serum potassium and ECG monitoring.. The standard adult dose of CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min. May be repeated as needed based on serum calcium levels and clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity from potassium chloride or dextrose at standard concentrations. Potassium chloride is a normal constituent of body fluids; dextrose is a nutrient. No . CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies; calcium chloride is a normal blood constituent. First trimester: no known risk. Second and third trimesters: use only if clearly ne. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.